论文部分内容阅读
目的观察肺癌患者的血栓前状态及其与肺癌的生物学行为和临床进展的关系。方法用酶联免疫吸附法（ＥＬＩＳＡ）测定了２６例肺癌患者、２０例良性肺病患者及２０例正常人血浆Ｄ－二聚体（ＤＤ）和血管性假血友病因子（ＶＷＦ）含量。结果肺癌组血浆ＤＤ和ＶＷＦ明显高于良性肺病组及健康对照组（Ｐ＜０．０１）。肺癌组有远处转移者（Ⅲ、Ⅳ期）血浆ＤＤ和ＶＷＦ含量明显高于无远处转移者（Ⅱ期）（Ｐ＜０．０１）。结论肺癌患者存在血栓前状态；检测血浆中ＤＤ和ＶＷＦ可用作判断肺癌临床进展的血凝标志物。
Objective To observe the prethrombotic state of lung cancer patients and its relationship with the biological behavior and clinical progress of lung cancer. Methods Plasma D-dimer (DD) and von Willebrand factor (VWF) levels in 26 patients with lung cancer, 20 patients with benign lung disease and 20 normal controls were determined by enzyme-linked immunosorbent assay (ELISA). Results Plasma DD and VWF in lung cancer group were significantly higher than those in benign lung disease group and healthy control group (P<0.01). The plasma levels of DD and VWF in patients with distant metastasis (stage III and IV) in lung cancer group were significantly higher than those without distant metastasis (stage II) (P<0.01). Conclusion There is a prethrombotic state in lung cancer patients. The detection of DD and VWF in plasma can be used as a marker for judging the clinical progression of lung cancer.